Evidence map›Paper›PMID 24348833›Full record

ArticleOncology letters2014

Low dose of interferon-α improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study.

Yun-Fei Li, Qin-Zhang Wang, Tao-Tao Zhang, Lei Li, Jiang-Ping Wang, Guo-Fu Ding, DA-Lin He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Natural and Engineered Cytokines as Cancer Therapeutics.Annual review of cancer biology · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Type I interferons in anticancer immunity.Nature reviews. Immunology · 2015
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yun-Fei LiDepartment of Urology, First Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China ; Department of Urology, First Hospital of Shihezi University, Shihezi, Xinjiang 832008, P.R. China ; Department of Urology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Qin-Zhang WangDepartment of Urology, First Hospital of Shihezi University, Shihezi, Xinjiang 832008, P.R. China.
Tao-Tao ZhangDepartment of Urology, First Hospital of Shihezi University, Shihezi, Xinjiang 832008, P.R. China ; Department of Urology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Lei LiDepartment of Urology, First Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.
Jiang-Ping WangDepartment of Urology, First Hospital of Shihezi University, Shihezi, Xinjiang 832008, P.R. China.
Guo-Fu DingDepartment of Urology, First Hospital of Shihezi University, Shihezi, Xinjiang 832008, P.R. China.
DA-Lin HeDepartment of Urology, First Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to test whether a low dose of interferon-α-2b (IFN-α2b) enhances the clinical outcome of docetaxel (DXT) in patients with castration-resistant prostate cancer (CRPC). A prospective controlled trial of 40 CRPC patients receiving 5 mg of prednisone twice daily was conducted, where patients were randomly assigned to be administered 75 mg/m

Indexed as

castration-resistant prostate cancerdocetaxelinterferon-α-2b

Identifiers

PMID24348833
PMCPMC3861530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.